Larry Wood - Edwards Lifesciences Co Replacement
| EWL Stock | EUR 70.08 0.26 0.37% |
Insider
Larry Wood is Co Replacement of Edwards Lifesciences
| Age | 57 |
| Phone | 949 250 2500 |
| Web | https://www.edwards.com |
Larry Wood Latest Insider Activity
Tracking and analyzing the buying and selling activities of Larry Wood against Edwards Lifesciences stock is an integral part of due diligence when investing in Edwards Lifesciences. Larry Wood insider activity provides valuable insight into whether Edwards Lifesciences is net buyers or sellers over its current business cycle. Note, Edwards Lifesciences insiders must abide by specific rules, including filing SEC forms every time they buy or sell Edwards Lifesciences'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Larry Wood over a year ago Exercise or conversion by Larry Wood of 8660 shares of Edwards Lifesciences subject to Rule 16b-3 | ||
Larry Wood over a year ago Exercise or conversion by Larry Wood of 8660 shares of Edwards Lifesciences subject to Rule 16b-3 | ||
Larry Wood over a year ago Exercise or conversion by Larry Wood of 8660 shares of Edwards Lifesciences subject to Rule 16b-3 | ||
Larry Wood over a year ago Exercise or conversion by Larry Wood of 8660 shares of Edwards Lifesciences subject to Rule 16b-3 |
Edwards Lifesciences Management Efficiency
The company has return on total asset (ROA) of 0.1334 % which means that it generated a profit of $0.1334 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2614 %, meaning that it generated $0.2614 on every $100 dollars invested by stockholders. Edwards Lifesciences' management efficiency ratios could be used to measure how well Edwards Lifesciences manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Zelko Relic | Align Technology | 58 | |
| Andre Hartung | Siemens Healthineers AG | N/A | |
| Andrea Wainer | Abbott Laboratories | 53 | |
| Christian Klaussner | Siemens Healthineers AG | N/A | |
| Jason Beach | Stryker | N/A | |
| Robert Cohen | Stryker | N/A | |
| John Sorenson | Boston Scientific | 55 | |
| Michael Spears | Insulet | 58 | |
| James Young | Abbott Laboratories | N/A | |
| Ivan Fong | Medtronic PLC | 62 | |
| Bret Christensen | Insulet | 52 | |
| Jonathan Monson | Boston Scientific | N/A | |
| Emory Wright | Align Technology | 53 | |
| John Morici | Align Technology | 56 | |
| Daniel Brennan | Boston Scientific | 57 | |
| Deborah CPA | Insulet | 53 | |
| Susan Lisa | Boston Scientific | 54 | |
| Joseph Hogan | Align Technology | 66 | |
| Joseph Fitzgerald | Boston Scientific | 59 | |
| Simon Beard | Align Technology | 56 | |
| Robert Ford | Abbott Laboratories | 49 | |
Management Performance
| Return On Equity | 0.26 | |||
| Return On Asset | 0.13 |
Edwards Lifesciences Leadership Team
Elected by the shareholders, the Edwards Lifesciences' board of directors comprises two types of representatives: Edwards Lifesciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Edwards. The board's role is to monitor Edwards Lifesciences' management team and ensure that shareholders' interests are well served. Edwards Lifesciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Edwards Lifesciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Scott Ullem, Co CFO | ||
| Larry Wood, Co Replacement | ||
| Mark Wilterding, VP Relations | ||
| Donald Bobo, Corp Devel | ||
| Todd Brinton, Co Officer | ||
| Arnold Pinkston, Corp Counsel | ||
| Dirksen Lehman, Co Affairs | ||
| Michael Mussallem, Chairman CEO | ||
| JeanLuc Lemercier, Middle Europe | ||
| Christine McCauley, Co HR |
Edwards Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Edwards Lifesciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.26 | |||
| Return On Asset | 0.13 | |||
| Profit Margin | 0.28 % | |||
| Operating Margin | 0.33 % | |||
| Current Valuation | 43.48 B | |||
| Shares Outstanding | 608.31 M | |||
| Shares Owned By Insiders | 0.82 % | |||
| Shares Owned By Institutions | 86.92 % | |||
| Price To Earning | 45.19 X | |||
| Price To Book | 7.49 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Edwards Stock
Edwards Lifesciences financial ratios help investors to determine whether Edwards Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Edwards with respect to the benefits of owning Edwards Lifesciences security.